Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy : A Case-Control Analysis of over 10,000 Treatments
Copyright © 2021 SIR. Published by Elsevier Inc. All rights reserved..
PURPOSE: To evaluate the safety of radiofrequency ablation (RFA) for liver tumors in patients on antithrombotic therapy.
MATERIALS AND METHODS: A total of 10,653 consecutive RFA treatments in 3,485 patients with liver tumors were analyzed. The incidence of complications was analyzed on a treatment basis. The treatments for patients who had received antithrombotic medication up to 1 week prior to RFA comprised the antithrombotic therapy group (n = 806), and the others comprised the control group (n = 9,847). Antithrombotic agents were ceased prior to RFA (aspirin, ticlopidine, clopidogrel, and prasugrel ceased 7 days before RFA; cilostazol, 2 or 3 days before RFA; warfarin, 3 days before RFA; and direct oral anticoagulants, 1 day before RFA) and resumed as soon as possible after RFA. Logistic regression analysis was performed to assess whether the antithrombotic therapy increased the risk of hemorrhagic complications.
RESULTS: Hemorrhagic complications were diagnosed after 6 treatments (0.7%) in the antithrombotic group and 48 (0.5%) in the control group, and there was no significant difference between the groups (P = .30). In 3 treatments, hemorrhage was diagnosed on or after 8 days of RFA, all of which were in the antithrombotic group. Thrombotic complications were diagnosed after 2 treatments (0.2%) in the antithrombotic group and after 5 (0.1%) in the control group. In a multivariate analysis, receiving antithrombotic therapy was not an independent risk factor for hemorrhagic complications (adjusted odds ratio, 1.52; 95% confidence interval, 0.60-3.87; P = .38).
CONCLUSIONS: RFA of liver tumors in patients on antithrombotic therapy is generally safe with appropriate cessation and resumption. Late-onset hemorrhage should be noted in the patients on antithrombotic therapy.
| Errataetall: |
CommentIn: Radiol Imaging Cancer. 2021 Sep;3(5):e219019. - PMID 34533379 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Journal of vascular and interventional radiology : JVIR - 32(2021), 6 vom: 12. Juni, Seite 869-877 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Uchino, Koji [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 16.08.2021 Date Revised 25.09.2021 published: Print-Electronic CommentIn: Radiol Imaging Cancer. 2021 Sep;3(5):e219019. - PMID 34533379 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jvir.2021.02.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32246949X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32246949X | ||
| 003 | DE-627 | ||
| 005 | 20231225182115.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jvir.2021.02.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM32246949X | ||
| 035 | |a (NLM)33689831 | ||
| 035 | |a (PII)S1051-0443(21)00385-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Uchino, Koji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy |b A Case-Control Analysis of over 10,000 Treatments |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2021 | ||
| 500 | |a Date Revised 25.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Radiol Imaging Cancer. 2021 Sep;3(5):e219019. - PMID 34533379 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 SIR. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: To evaluate the safety of radiofrequency ablation (RFA) for liver tumors in patients on antithrombotic therapy | ||
| 520 | |a MATERIALS AND METHODS: A total of 10,653 consecutive RFA treatments in 3,485 patients with liver tumors were analyzed. The incidence of complications was analyzed on a treatment basis. The treatments for patients who had received antithrombotic medication up to 1 week prior to RFA comprised the antithrombotic therapy group (n = 806), and the others comprised the control group (n = 9,847). Antithrombotic agents were ceased prior to RFA (aspirin, ticlopidine, clopidogrel, and prasugrel ceased 7 days before RFA; cilostazol, 2 or 3 days before RFA; warfarin, 3 days before RFA; and direct oral anticoagulants, 1 day before RFA) and resumed as soon as possible after RFA. Logistic regression analysis was performed to assess whether the antithrombotic therapy increased the risk of hemorrhagic complications | ||
| 520 | |a RESULTS: Hemorrhagic complications were diagnosed after 6 treatments (0.7%) in the antithrombotic group and 48 (0.5%) in the control group, and there was no significant difference between the groups (P = .30). In 3 treatments, hemorrhage was diagnosed on or after 8 days of RFA, all of which were in the antithrombotic group. Thrombotic complications were diagnosed after 2 treatments (0.2%) in the antithrombotic group and after 5 (0.1%) in the control group. In a multivariate analysis, receiving antithrombotic therapy was not an independent risk factor for hemorrhagic complications (adjusted odds ratio, 1.52; 95% confidence interval, 0.60-3.87; P = .38) | ||
| 520 | |a CONCLUSIONS: RFA of liver tumors in patients on antithrombotic therapy is generally safe with appropriate cessation and resumption. Late-onset hemorrhage should be noted in the patients on antithrombotic therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 700 | 1 | |a Tateishi, Ryosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Wake, Taijiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kinoshita, Mizuki Nishibatake |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagomi, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Nakatsuka, Takuma |e verfasserin |4 aut | |
| 700 | 1 | |a Minami, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Masaya |e verfasserin |4 aut | |
| 700 | 1 | |a Enooku, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagawa, Hayato |e verfasserin |4 aut | |
| 700 | 1 | |a Shiina, Shuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Koike, Kazuhiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of vascular and interventional radiology : JVIR |d 1997 |g 32(2021), 6 vom: 12. Juni, Seite 869-877 |w (DE-627)NLM012603120 |x 1535-7732 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:6 |g day:12 |g month:06 |g pages:869-877 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jvir.2021.02.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2021 |e 6 |b 12 |c 06 |h 869-877 | ||